Abstract
The majority of patients diagnosed with pancreatic cancer have inoperable disease at the time of presentation. For this reason, systemic treatment is the cornerstone of therapy and more options for systemic therapy have now become available than were a decade ago. In this short review, we will give an overview on the systemic therapeutic landscape in 2018 and briefly discuss the challenging topic of neoadjuvant therapy. However, there are a lot of unsolved questions and an urgent need of more clinical trials and new therapies. In conclusion, despite recent advances, there remains much room for improvement in all aspects of treatment for pancreatic cancer.
Highlights
Ductal pancreatic cancer currently represents the seventh most common cause of cancer mortality worldwide, accounting for about 4% of cancer-related deaths in males and females [1]
Standard treatment for patients with resectable pancreatic cancer is surgery followed by adjuvant chemotherapy
A series of studies has established that 6 months of adjuvant chemotherapy with either infusional gemcitabine or infusional fluorouracil (5-FU) improves overall survival
Summary
Ductal pancreatic cancer currently represents the seventh most common cause of cancer mortality worldwide, accounting for about 4% of cancer-related deaths in males and females [1]. The overall 5-year survival rate among patients with pancreatic cancer is less than 5% [2, 3]. Standard treatment for patients with resectable pancreatic cancer is surgery followed by adjuvant chemotherapy.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
